Evidence map›Paper›PMID 38356863›Full record

ArticleRespirology case reports2024

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy.

Yuki Haruta, Masanori Azuma, Toshikatsu Sado, Ryuichi Saito, Yoshimune Miyazaki, Akihiro Noda, Reina Kitagawa, Yasutaka Hori, Sayaka Fujimoto, Yoshinori Hasegawa and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respirology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yuki HarutaDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Masanori AzumaDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.ORCID https://orcid.org/0009-0008-6049-9161
Toshikatsu SadoDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Ryuichi SaitoDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Yoshimune MiyazakiDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Akihiro NodaDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Reina KitagawaDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Yasutaka HoriDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Sayaka FujimotoDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Yoshinori HasegawaDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Tetsuya UedaDepartment of Respiratory Medicine Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Ryosuke YamamuraDepartment of Hematology Osaka Saiseikai Nakatsu Hospital Osaka Japan.
Saiseikai Nakatsu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab-induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.

Indexed as

factor V inhibitorshaemophiliahem‐irAEimmune checkpoint inhibitors

Identifiers

PMID38356863
PMCPMC10866682
OpenAlexW4391920923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.